EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Symptom Prevalence and Impact on Lung Cancer Risk in the SUMMIT Study

Monica L Mullin, Andrew W Creamer, Amyn Bhamani, Priyam Verghese, Ruth Prendecki, Chuen R Khaw, Sindhu B Naidu, Tanya Patrick, Jennifer L Dickson, Carolyn Horst, Sophie Tisi, Helen Hall und 10 weitere

CHEST · 2026-11 · 170 (5) · 1614-1624

DOI: 10.1016/j.chest.2026.03.048 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift CHEST, 2026-11. Verfasst von Monica L Mullin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respirology, University of British Columbia, Vancouver, BC, Canada; Lungs for Living Research Centre, UCL Respiratory, University Colle…. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer screening is now widely adopted across health care systems. Screening typically occurs in asymptomatic individuals. Because symptoms of lung cancer overlap with those of chronic conditions, defining asymptomatic screening is challenging. This study outlines the frequency of symptomatic participants in a lung cancer screening trial. RESEARCH QUESTION: How common are respiratory and red flag symptoms in lung cancer screening participants, and how do these symptoms impact screening outcomes? STUDY DESIGN AND METHODS: The SUMMIT study was a prospective observational cohort study to assess the implementation of low-dose CT screening for lung cancer. Baseline clinical assessments collected self-reported symptoms, medical history, demographics, and spirometry. Hemoptysis (in last year) and unintentional weight loss (≥ 5 kg in 3 months) were classified as red flag symptoms, and cough (acute: onset 6 weeks) and dyspnea (modified Medical Research Council scale score ≥ 1) were classified as nonspecific symptoms. Lung cancer diagnoses within 1 year were ascertained. Multivariable logistic regression was used to assess associations between symptoms and lung cancer. RESULTS: Among 13,035 participants eligible for a baseline LDCT scan, 76% (n = 9,859) reported at least 1 symptom. Cough was present in 36% (n = 4,707), and 66% of participants reported dyspnea. Only 6% of participants reported red flag symptoms, including hemoptysis and weight loss. The presence of any of these symptoms was associated with higher likelihood of lung cancer diagnosis in the year after assessment (OR, 1.45; P = .03, adjusted for other baseline factors). INTERPRETATION: Our results show that symptoms are commonly reported in those undergoing lung cancer screening and those with symptoms are more likely to be diagnosed with lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerHumansFemaleProspective StudiesPrevalenceTomography, X-Ray ComputedCoughMaleHemoptysisMiddle AgedDyspneaAgedWeight LossRisk Factors

Stichwörter der Autor:innen

cancer riskcoughlung cancerlung cancer screeningsymptoms

Autor:innen und Institutionen

  • Department of Respirology, University of British Columbia, Vancouver, BC, Canada; Lungs for Living Research Centre, UCL Respiratory, University College London, London, England.
  • Lungs for Living Research Centre, UCL Respiratory, University College London, London, England.
  • Centre for Cancer Screening, Prevention, Detection and Early Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, England.
  • CRUK & UCL Cancer Trials Centre, University College London, London, England.
  • University College London Hospitals NHS Foundation Trust, London, England.
  • Royal Brompton and Harefield Hospitals, Imperial College NHS Foundation Trust, London, England; National Heart and Lung Institute, Imperial College, London, England.

Förderung

  • Wellcome Trust

Zitieren

APA

Mullin, M. L., Creamer, A. W., Bhamani, A., Verghese, P., Prendecki, R., Khaw, C. R., Naidu, S. B., Patrick, T., Dickson, J. L., Horst, C., Tisi, S., Hall, H., Quaife, S. L., Hacker, A. M., Farrelly, L., McCabe, J., Dawadi, S., Nair, A., Devaraj, A., …, & SUMMIT Consortium (2026). Symptom Prevalence and Impact on Lung Cancer Risk in the SUMMIT Study. CHEST, 170(5), 1614-1624. https://doi.org/10.1016/j.chest.2026.03.048

Vancouver

Mullin ML, Creamer AW, Bhamani A, Verghese P, Prendecki R, Khaw CR, et al. Symptom Prevalence and Impact on Lung Cancer Risk in the SUMMIT Study. CHEST. 2026;170(5):1614-1624. doi:10.1016/j.chest.2026.03.048

BibTeX
@article{Mullin2026,
  author = {Mullin, Monica L and Creamer, Andrew W and Bhamani, Amyn and Verghese, Priyam and Prendecki, Ruth and Khaw, Chuen R and Naidu, Sindhu B and Patrick, Tanya and Dickson, Jennifer L and Horst, Carolyn and Tisi, Sophie and Hall, Helen and Quaife, Samantha L and Hacker, Anne-Marie and Farrelly, Laura and McCabe, John and Dawadi, Shrinkhala and Nair, Arjun and Devaraj, Anand and Hackshaw, Allan and Janes, Sam M and SUMMIT Consortium, SUMMIT Consortium},
  title = {Symptom Prevalence and Impact on Lung Cancer Risk in the SUMMIT Study},
  journal = {CHEST},
  year = {2026},
  volume = {170},
  number = {5},
  pages = {1614--1624},
  doi = {10.1016/j.chest.2026.03.048}
}
Kostenlos starten →